Physician profile
Maria E Pena
NPI 1487815361
$238,924.12
in general payments reported to CMS, 2019-2025
33 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $58K · 2021: $420 · 2022: $64K · 2023: $12K · 2024: $38K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $5,523 · Consulting Fee: $3,750 · Food and Beverage: $3,744 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,216.94 |
| Travel and Lodging | $5,522.62 |
| Consulting Fee | $3,750.00 |
| Food and Beverage | $3,743.52 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203,749.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $32,629.85 | 2019-2021 | |
| Lilly USA, LLC | $355.16 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $313.92 | 2019-2025 | Freestyle Libre 3, Aveir |
| Mannkind Corporation | $308.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $193.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.95 | 2020-2025 | Jardiance |
| Amgen INC. | $129.07 | 2023-2025 | Evenity, Prolia, Tepezza |
| Madrigal Pharmaceuticals | $114.17 | 2025 | Rezdiffra |
| Abbvie INC. | $99.28 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $81.25 | 2025 | Unithroid |
| Opko Pharmaceuticals, LLC | $70.91 | 2024 | Rayaldee |
| Corcept Therapeutics | $62.56 | 2024-2025 | Korlym |
| Ascensia Diabetes Care US INC. | $59.11 | 2025 | |
| Kyowa Kirin, INC. | $53.91 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $52.88 | 2024 | |
| Currax Pharmaceuticals LLC | $45.53 | 2024-2025 | Contrave |
| Medtronic, INC. | $40.68 | 2024-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $40.13 | 2025 | Recorlev |
| Integra Lifesciences Corporation | $37.30 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Rhythm Pharmaceuticals, INC. | $35.97 | 2025 | Imcivree |
| Cvrx, INC. | $35.15 | 2024 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $31.01 | 2025 | Strensiq |
| Beta Bionics, INC. | $24.73 | 2024 | Ilet Bionic Pancreas |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.43 | 2025 | Xifaxan |
| Chiesi USA, INC. | $21.78 | 2024 | Mycapssa |
| Insulet Corporation | $21.40 | 2025 | Omnipod |
| Lexicon Pharmaceuticals, INC. | $20.24 | 2024 | |
| Almatica Pharma LLC | $20.01 | 2021 | |
| Recordati_rare_diseases_inc. | $17.13 | 2025 | Isturisa |
| Eisai INC. | $17.02 | 2025 | |
| Philips North America LLC | $16.64 | 2024 | (Ck4) Mcot |
| Cequr Corporation | $10.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.